PROK Stock Overview
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ProKidney Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.71 |
| 52 Week High | US$13.51 |
| 52 Week Low | US$1.12 |
| Beta | 1.29 |
| 1 Month Change | 70.44% |
| 3 Month Change | 90.85% |
| 1 Year Change | -72.32% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -73.19% |
Recent News & Updates
Shareholder Returns
| PROK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.9% | 1.0% | 1.2% |
| 1Y | -72.3% | 0.7% | 24.9% |
Price Volatility
| PROK volatility | |
|---|---|
| PROK Average Weekly Movement | 19.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PROK's share price has been volatile over the past 3 months.
Volatility Over Time: PROK's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 163 | Bruce Culleton | www.prokidney.com |
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company’s lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp. Fundamentals Summary
| PROK fundamental statistics | |
|---|---|
| Market cap | US$621.52m |
| Earnings (TTM) | -US$35.47m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.7x
P/E RatioIs PROK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PROK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$35.47m |
| Earnings | -US$35.47m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PROK perform over the long term?
See historical performance and comparison